Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDR | P35968 | 5/20 | 0.61 |
| ▸ | RET | P07949 | 4/20 | 0.61 |
| ▸ | FLT3 | P36888 | 4/20 | 0.61 |
| ▸ | PDGFRB | P09619 | 4/20 | 0.61 |
| ▸ | ALK | Q9UM73 | 4/20 | 0.61 |
| ▸ | TLK2 | Q86UE8 | 3/20 | 0.61 |
| ▸ | CDK5 | Q00535 | 3/20 | 0.61 |
| ▸ | NTRK1 | P04629 | 3/20 | 0.61 |
| ▸ | JAK3 | P52333 | 2/20 | 0.61 |
| ▸ | PDPK1 | O15530 | 2/20 | 0.61 |
| ▸ | DAPK3 | O43293 | 2/20 | 0.61 |
| ▸ | PRKD3 | O94806 | 2/20 | 0.61 |
| ▸ | MAP4K4 | O95819 | 2/20 | 0.61 |
| ▸ | LCK | P06239 | 2/20 | 0.61 |
| ▸ | FYN | P06241 | 2/20 | 0.61 |
| ▸ | CSF1R | P07333 | 2/20 | 0.61 |
| ▸ | LTK | P29376 | 2/20 | 0.61 |
| ▸ | MAPK8 | P45983 | 2/20 | 0.61 |
| ▸ | CSNK1A1 | P48729 | 2/20 | 0.61 |
| ▸ | CDK7 | P50613 | 2/20 | 0.61 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL680846 | 1.00 | KDR (0.61) | KDRRETFLT3PDGFRBALK | |
| SCHEMBL14588617 | 0.80 | MAPT (0.60) | KDRRETFLT3PDGFRBALK | |
| SCHEMBL5728101 | 0.79 | MAPT (0.64) | KDRRETFLT3PDGFRBALK | |
| SCHEMBL5728098 | 0.79 | MAPT (0.64) | KDRRETFLT3PDGFRBALK | |
| SCHEMBL13038796 | 0.76 | PDPK1 (1.00) | KDRRETFLT3PDGFRBALK | |
| SCHEMBL30898303 | 0.76 | PDPK1 (1.00) | KDRRETFLT3PDGFRBALK | |
| SCHEMBL1162655 | 0.76 | PDPK1 (1.00) | KDRRETFLT3PDGFRBALK | |
| SCHEMBL29385385 | 0.76 | PDPK1 (1.00) | KDRRETFLT3PDGFRBALK | |
| SCHEMBL30898301 | 0.76 | PDPK1 (1.00) | KDRRETFLT3PDGFRBALK | |
| SCHEMBL1162656 | 0.76 | PDPK1 (1.00) | KDRRETFLT3PDGFRBALK |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 37 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240058367-A1 | COMPOSITIONS COMPRISING DECITABINE AND TETRAHYDROURIDINE AND USES THEREOF | THE BOARD OF TRUSTEES OF THE UNIVERSITY OF ILLINOIS (US) | 2024-02-22 | — | — | US | disclosed |
| US-11786543-B2 | Compositions comprising decitabine and tetrahydrouridine and uses thereof | BOARD OF TRUSTEES OF THE UNIVERSITY OF ILLINOIS (US) | 2023-10-17 | — | — | US | disclosed |
| US-20220023328-A1 | COMPOSITIONS COMPRISING DECITABINE AND TETRAHYDROURIDINE AND USES THEREOF | THE BOARD OF TRUSTEES OF THE UNIVERSITY OF ILLINOIS (US) | 2022-01-27 | — | — | US | disclosed |
| US-20200155587-A1 | COMPOSITIONS COMPRISING DECITABINE AND TETRAHYDROURIDINE AND USES THEREOF | BOARD OF TRUSTEES OF THE UNIVERSITY OF ILLINOIS | 2020-05-21 | — | — | US | disclosed |
| US-20180325932-A1 | COMPOSITIONS COMPRISING DECITABINE AND TETRAHYDROURIDINE AND USES THEREOF | BOARD OF TRUSTEES OF THE UNIVERSITY OF ILLINOIS | 2018-11-15 | — | — | US | disclosed |
| US-9895391-B2 | Compositions comprising decitabine and tetrahydrouridine and uses thereof | THE BOARD OF TRUSTEES OF THE UNIVERSITY OF ILLINOIS (US) | 2018-02-20 | — | — | US | disclosed |
| US-20170014440-A1 | COMPOSITIONS COMPRISING DECITABINE AND TETRAHYDROURIDINE AND USES THEREOF | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2017-01-19 | — | — | US | disclosed |
| US-9265785-B2 | Compositions comprising decitabine and tetrahydrouridine and uses thereof | THE BOARD OF TRUSTEES OF THE UNIVERSITY OF ILLINOIS (US) | 2016-02-23 | — | — | US | disclosed |
| US-9259469-B2 | Compositions comprising decitabine and tetrahydrouridine and uses thereof | THE BOARD OF TRUSTEES OF THE UNIVERSITY OF ILLINOIS (US) | 2016-02-16 | — | — | US | disclosed |
| EP-2381780-B1 | COMPOSITIONS COMPRISING DECITABINE AND TETRAHYDROURIDINE AND USES THEREOF | UNIV ILLINOIS (US) | 2015-02-25 | — | — | EP | disclosed |
| US-20070027149-A1 | 3-(4-amidopyrrol-2-ylmethylidene)-2-indolinone der derivatives as protein kinase inhibitors | SUGEN, INC. | 2007-02-01 | — | — | US | disclosed |
| EP-1370554-B1 | 3-(4-AMIDOPYRROL-2-YLMETHYLIDENE)-2-INDOLINONE DERIVATIVES AS PROTEIN KINASE INHIBITORS | PHARMACIA & UPJOHN CO LLC (US) | 2005-10-19 | — | — | EP | disclosed |
| US-20040102510-A1 | 3-(4-amidopyrrol-2-ylmethlidene)-2-indolinone derivatives as protein kinase inhibitors | SUGEN, INC. | 2004-05-27 | — | — | US | disclosed |
| US-20040102510-A1 | 3-(4-amidopyrrol-2-ylmethlidene)-2-indolinone derivatives as protein kinase inhibitors | SUGEN, INC. | 2004-05-27 | — | — | US | disclosed |
| EP-1370554-A1 | 3-(4-AMIDOPYRROL-2-YLMETHYLIDENE)-2-INDOLINONE DERIVATIVES AS PROTEIN KINASE INHIBITORS | PHARMACIA & UPJOHN COMPANY (US) | 2003-12-17 | — | — | EP | disclosed |
| US-6653308-B2 | Anticancer agents; antidiabetic agents; antiinflammatory agents | SUGEN, INC. | 2003-11-25 | — | — | US | disclosed |
| US-6653308-B2 | Anticancer agents; antidiabetic agents; antiinflammatory agents | SUGEN, INC. | 2003-11-25 | — | — | US | disclosed |
| US-20030092917-A1 | 3-(4-amidopyrrol-2-ylmethylidene)-2-indolinone derivatives as portein kinase inhibitors | SUGEN, INC. | 2003-05-15 | — | — | US | disclosed |
| US-20030092917-A1 | 3-(4-amidopyrrol-2-ylmethylidene)-2-indolinone derivatives as portein kinase inhibitors | SUGEN, INC. | 2003-05-15 | — | — | US | disclosed |
| WO-2002066463-A1 | 3-(4-AMIDOPYRROL-2-YLMETHLIDENE)-2-INDOLINONE DERIVATIVES AS PROTEIN KINASE INHIBITORS | PHARMACIA & UPJOHN COMPANY (US) | 2002-08-29 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040102510-A1 | 3-(4-amidopyrrol-2-ylmethlidene)-2-indolinone derivatives as protein kinase inhibitors | MAP3K15, MAP3K19, MAP3K9 | KDR 1384/4885RET 433/4885FLT3 511/4885 |
| US-20030092917-A1 | 3-(4-amidopyrrol-2-ylmethylidene)-2-indolinone derivatives as portein kinase inhibitors | PDPK1, MKNK1, PKN2 | KDR 1298/4885RET 780/4885FLT3 1652/4885 |
| US-20070027149-A1 | 3-(4-amidopyrrol-2-ylmethylidene)-2-indolinone der derivatives as protein kinase inhibitors | PDPK1, MAP4K2, MAP4K3 | KDR 1334/4885RET 431/4885FLT3 571/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.